Colorado is currently home to 1810 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry
NCT06633029
Recruiting
A retrospective multicenter, observational design intended to capture data on pediatrics (weighing between 8 - 20 kg) who underwent continuous renal replacement therapy (CRRT) using the HF20 set. Data will be compared with a similar population (weighting 8-20 kg) from the ppCRRT registry who received CRRT with Prismaflex M60 sets.
Gender:
ALL
Ages:
All
Trial Updated:
02/03/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients
Register for Updates
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
NCT06532734
Recruiting
To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/03/2025
Locations: ACUTE Center for Eating Disorders and Severe Malnutrition, Denver, Colorado
Conditions: Barrett Esophagus, Anorexia Nervosa, Binge Eating/Purging Type, Rumination, Vomiting, Eating Disorders, Esophageal Adenocarcinoma
Register for Updates
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Colorado Heart and Vascular, Golden, Colorado
Conditions: Coronary Artery Disease
Register for Updates
Restoration Anatomic Acetabular Shell Revision Study
NCT05591859
Recruiting
This study will be a non-randomized, ambidirectional (retrospective and prospective) study where all subjects will be followed prospectively. The study will evaluate the survivorship of the RAS acetabular component in a previously failed total hip arthroplasty (THA) in a consecutive series of subjects who meet the eligibility criteria.
Gender:
ALL
Ages:
All
Trial Updated:
02/03/2025
Locations: Regents of the University of Colorado, Denver, Colorado
Conditions: Arthropathy, Hip Arthropathy, Hip Osteoarthritis
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: SCRI HealthOne, Denver, Colorado
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Rocky Mountain Cancer Center, LLP, Boulder, Colorado
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation
Register for Updates
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: USOR - Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado
Conditions: Myelofibrosis
Register for Updates
Microbiome in Head and Neck Squamous Cell Carcinoma
NCT05837221
Recruiting
This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/31/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Head and Neck Cancer, Lip Cancer, Oral Cancer, Pharynx Cancer
Register for Updates
Study of Placental Function in Healthy and Pathological Pregnancies
NCT02321007
Recruiting
The purpose of this study is to establish a tissue and data repository consisting of samples of human placentas, umbilical cord blood, and maternal blood, collected at the time of delivery. Specimens will be used in cellular, molecular, and functional studies to learn more about changes in placental structure and function, which can result in serious pregnancy complications and determine life-long health by programming the fetus for future metabolic and cardiovascular disease.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
01/31/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Pregnancy
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Register for Updates
Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development
NCT06379971
Recruiting
The goal of this study is to determine if providing a nutritional supplement, phosphatidylcholine, to pregnant women who have used cannabis products during the current pregnancy improves the offspring\'s brain-related development during the first 3 months. Participating pregnant women will receive either phosphatidylcholine or a placebo from approximately 16 weeks gestation through birth. The primary outcomes are the child\'s brain responses to sound at 4 weeks corrected age and infant b... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
01/29/2025
Locations: UC Health, Aurora, Colorado
Conditions: Child Development, Cannabis Use
Register for Updates